Posted by Michael Wonder on 07 Feb 2018
Patients to benefit from myeloma treatment through CDF deal
7 February 2018 - Up to 1,600 patients with multiple myeloma could benefit from a new oral pill after NICE recommends ixazomib, also known as Ninlaro, for use within the Cancer Drugs Fund.
Takeda, who market the drug, struck a deal with NHS England after NICE said ixazomib should be available whilst more evidence is gathered on its value.
Evidence showed that ixazomib is effective at slowing down disease progression compared with standard treatment but it is not clear whether it helps people live longer.
